The funds will help Cleerly increase its headcount and widen its market reach to increase patient and physician access to its technology-enabled care pathway across the full spectrum of disease presentation
Cleerly raises $192m in Series C funding round. (Credit: Shahid Abdullah from Pixabay)
US-based heart care company Cleerly announced the closing of a Series C financing round of $192m, bringing the total raised by the company to $248m including a Series B investment round from last year.
The funding round was led by funds and accounts advised by T. Rowe Price Associates, T. Rowe Price Investment Management and Fidelity Management and Research Company.
Additional investors from the pharmaceutical, technology and healthcare industries, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis have participated in the funding round.
The round also saw participation from Cleerly’s existing investors, which included Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, and DigiTx Partners.
With the funds, Cleerly will increase its headcount and widen its market reach to increase patient and physician access to its technology-enabled care pathway across the full spectrum of disease presentation.
This will help the firm to make sure that ongoing treatments are efficient for those who have that elevated risk or symptoms.
Additionally, Cleerly will spend money on more extensive outcomes research to make it the standard of care helping doctors diagnose and treat heart disease.
The firm said that more than a dozen multicentre clinical trials are underway at Cleerly, including a worldwide registry that will recruit more than 100,000 patients over the next 10 years.
Cleerly CEO and founder James Min said: “At Cleerly, we are passionate about our mission to create a new standard of care for heart disease.
“We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care.
“The status quo for heart health simply isn’t good enough – for patients, providers, or payors – and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”